Related Experiment Video
Updated: May 3, 2026
Refined Murine Model of Idiopathic Pulmonary Fibrosis
Published on: June 17, 2025
Dual targeting of MEK and PI3K pathways attenuates established and progressive pulmonary fibrosis
Satish K Madala1, Ramakrishna Edukulla1, Mukta Phatak2
1Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States of America.
Abstract:
Pulmonary fibrosis is often triggered by an epithelial injury resulting in the formation of fibrotic lesions in the lung, which progress to impair gas exchange and ultimately cause death. Recent clinical trials using drugs that target either inflammation or a specific molecule have failed, suggesting that multiple pathways and cellular processes need to be attenuated for effective reversal of established and progressive fibrosis. Although activation of MAPK and PI3K pathways have been detected in human fibrotic lung samples, the therapeutic benefits of in vivo modulation of the MAPK and PI3K pathways in combination are unknown. Overexpression of TGFα in the lung epithelium of transgenic mice results in the formation of fibrotic lesions similar to those found in human pulmonary fibrosis, and previous work from our group shows that inhibitors of either the MAPK or PI3K pathway can alter the progression of fibrosis. In this study, we sought to determine whether simultaneous inhibition of the MAPK and PI3K signaling pathways is a more effective therapeutic strategy for established and progressive pulmonary fibrosis. Our results showed that inhibiting both pathways had additive effects compared to inhibiting either pathway alone in reducing fibrotic burden, including reducing lung weight, pleural thickness, and total collagen in the lungs of TGFα mice. This study demonstrates that inhibiting MEK and PI3K in combination abolishes proliferative changes associated with fibrosis and myfibroblast accumulation and thus may serve as a therapeutic option in the treatment of human fibrotic lung disease where these pathways play a role.
Insights
Simultaneous inhibition of MAPK and PI3K pathways offers a promising therapeutic strategy for pulmonary fibrosis. Combining these treatments significantly reduced fibrotic burden in mice, suggesting a novel approach for human fibrotic lung disease.
Area of Science:
- Pulmonary Medicine
- Cellular Biology
- Pharmacology
Background:
- Pulmonary fibrosis involves lung fibrotic lesions impairing gas exchange, often leading to death.
- Previous therapeutic strategies targeting single pathways or inflammation have shown limited success in clinical trials.
- Both MAPK and PI3K pathways are implicated in human fibrotic lung disease, but their combined therapeutic potential is unexplored.
Purpose of the Study:
- To investigate the efficacy of simultaneous inhibition of MAPK and PI3K signaling pathways in a mouse model of pulmonary fibrosis.
- To determine if combined pathway inhibition offers superior therapeutic benefits compared to targeting individual pathways.
Main Methods:
- Utilized a transgenic mouse model with TGFα overexpression in lung epithelium, mimicking human pulmonary fibrosis.
- Administered inhibitors targeting both MAPK (MEK) and PI3K pathways simultaneously.
- Assessed fibrotic burden by measuring lung weight, pleural thickness, and total collagen content.
Main Results:
- Combined inhibition of MEK and PI3K demonstrated additive effects in reducing fibrotic burden compared to single-pathway inhibition.
- Significant reductions in lung weight, pleural thickness, and total collagen were observed in mice treated with combined inhibitors.
- Simultaneous inhibition effectively abolished proliferative changes and myofibroblast accumulation associated with fibrosis.
Conclusions:
- Combined inhibition of MAPK and PI3K pathways represents a potentially more effective therapeutic strategy for established and progressive pulmonary fibrosis.
- This dual-pathway inhibition approach may offer a novel treatment option for human fibrotic lung diseases driven by these signaling pathways.
More Related Videos
Related Concept Videos
01:22PI3K/mTOR/AKT Signaling Pathway
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...